GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

NUVB · Jun 30, 2025

Nuvation Bio Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0000950170-25-104626General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

971.94% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-996.86% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

236.79% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

11.42% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

46.70% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-1315.73% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

566.15% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

248.93% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History9 statesHistory building

Jun 30, 20240/5 normalizedLevel 3 Sep 30, 20240/5 normalizedLevel 3 Dec 31, 20240/5 normalizedLevel 3 Mar 31, 20250/6 normalizedLevel 3 Jun 30, 20250/8 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20250/7 normalizedLevel 3 Mar 31, 20260/7 normalizedLevel 3 Jun 30, 20264/7 normalizedLevel 3

Period transition

What moved in the state?

Cash Generation Increased

Previous: -1382.20%
Current: -996.86%
Delta: 385.34%

Inventory Pressure Increased

Previous: 0.45%
Current: 11.42%
Delta: 10.97%

Margin Increased

Previous: 32.10%
Current: 46.70%
Delta: 14.60%

Profitability Increased

Previous: -1913.23%
Current: -1315.73%
Delta: 597.50%

R And D Intensity Decreased

Previous: 797.70%
Current: 566.15%
Delta: -231.55%

Sbc Intensity Decreased

Previous: 254.67%
Current: 248.93%
Delta: -5.73%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · NUVB Fundamental State →Has State · Nuvation Bio Inc. →Transitioned To · NUVB Fundamental State →Transitioned To · NUVB CASH_GENERATION_INCREASED →Transitioned To · NUVB INVENTORY_PRESSURE_INCREASED →Transitioned To · NUVB MARGIN_INCREASED →Transitioned To · NUVB PROFITABILITY_INCREASED →Transitioned To · NUVB R_AND_D_INTENSITY_DECREASED →Transitioned To · NUVB SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.